Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients - Repository

Full text

: https://doi.org/10.1038/s41467-024-45641-0

Abstract

Viral clearance, antibody response and the mutagenic effect of molnupiravir has not 77 been elucidated in at-risk populations. Non-hospitalised participants within 5 days of 78 SARS-CoV-2 symptoms randomised to receive molnupiravir (n=253) or Usual Care 79 (n=324) were recruited to study viral and antibody dynamics and the effect of molnupiravir on viral whole genome sequence from 1437 viral genomes. Molnupiravir accelerates viral load decline, but virus is detectable by Day 5 in most cases. At Day 14 (9 days post-treatment), molnupiravir is associated with significantly higher viral persistence and significantly lower anti-SARS-CoV-2 spike antibody titres compared to Usual Care. Serial sequencing reveals increased mutagenesis with molnupiravir treatment. Persistence of detectable viral RNA at Day 14 in the molnupiravir group is associated with higher transition mutations following treatment cessation. Viral viability at Day 14 is similar in both groups with post-molnupiravir treated samples cultured up to 9 days post cessation of treatment. The current 5-day molnupiravir course is too short. Longer courses should be tested to reduce the risk of potentially transmissible molnupiravir-mutated variants being generated.

Rights

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Cite as

Standing, J., Buggiotti, L., Guerra-Assuncao, J., Woodall, M., Ellis, S., Agyeman, A., Miller, C., Okechukwu, M., Kirkpatrick, E., Jacobs, A., Williams, C., Roy, S., Martin-Bernal, L., Williams, R., Smith, C., Sanderson, T., Ashford, F., Emmanuel, B., Afzal, Z., Sheilds, A., Richter, A., Dorward, J., Gbinigie, O., Lown, M., Francis, N., Jani, B., Richards, D., Rahman, N., Yu, L., Thomas, N., Hart, N., Evans, P., Andersson, M., Hayward, G., Hood, K., Nguyen-Van-Tam, J., Little, P., Hobbs, F., Khoo, S., Butler, C., Lowe, D., Breuer, J. & van Hecke, O. 2024, 'Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients', Nature Communications, 15, article no: 1652. https://doi.org/10.1038/s41467-024-45641-0

Downloadable citations

HTML BIB RIS

Identifiers

DOI: https://doi.org/10.1038/s41467-024-45641-0

Repository URI: https://eprints.gla.ac.uk/320633/